These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 15866706)
21. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Bayry J; Thirion M; Misra N; Thorenoor N; Delignat S; Lacroix-Desmazes S; Bellon B; Kaveri S; Kazatchkine MD Neurol Sci; 2003 Oct; 24 Suppl 4():S217-21. PubMed ID: 14598046 [TBL] [Abstract][Full Text] [Related]
22. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Elovaara I; Apostolski S; van Doorn P; Gilhus NE; Hietaharju A; Honkaniemi J; van Schaik IN; Scolding N; Soelberg Sørensen P; Udd B; Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075 [TBL] [Abstract][Full Text] [Related]
23. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736 [TBL] [Abstract][Full Text] [Related]
25. [Treatment with intravenous immunoglobulin in neurological diseases. A descriptive study of effects seen from the patient's and health services' perspectives]. Wintzell A; Eriksson T; Lundgren A; Petersson J Lakartidningen; 2008 May 21-27; 105(21):1571-5. PubMed ID: 18574994 [No Abstract] [Full Text] [Related]
26. Guidelines on the use of intravenous immune globulin for hematologic conditions. Anderson D; Ali K; Blanchette V; Brouwers M; Couban S; Radmoor P; Huebsch L; Hume H; McLeod A; Meyer R; Moltzan C; Nahirniak S; Nantel S; Pineo G; Rock G Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S9-56. PubMed ID: 17397769 [TBL] [Abstract][Full Text] [Related]
27. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Soelberg Sorensen P Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269 [TBL] [Abstract][Full Text] [Related]
28. Prospective evaluation of health related quality of life for pediatric patients with ureteropelvic junction obstruction. Parekh AD; Thomas JC; Trusler L; Ankerst DP; Deshpande JK; Adams MC; Pope JC; Brock JW J Urol; 2008 Nov; 180(5):2171-5; discussion 2175-6. PubMed ID: 18804796 [TBL] [Abstract][Full Text] [Related]
29. [Intravenous immunoglobulins in the treatment of glomerulopathies]. Floccari F; Palla R; Polito P; Campo S; Aloisi C; Buemi M G Ital Nefrol; 2007; 24(4):311-9. PubMed ID: 17659502 [TBL] [Abstract][Full Text] [Related]
30. [Use of high dose intravenous immunoglobulin in neurologic disease]. Korsak J; Zaleska B; Orłowska E; Kotowicz J Pol Merkur Lekarski; 2005 Jul; 19(109):98-101. PubMed ID: 16194039 [TBL] [Abstract][Full Text] [Related]
31. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions. Rigas M; Tandan R; Sterling RJ J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090 [TBL] [Abstract][Full Text] [Related]
32. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Pereira C; Tavares B; Carrapatoso I; Loureiro G; Faria E; Machado D; Chieira C Eur Ann Allergy Clin Immunol; 2007 Sep; 39(7):237-42. PubMed ID: 18237000 [TBL] [Abstract][Full Text] [Related]
33. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Emmi L; Chiarini F Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582 [TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin treatment in autoimmune neurological disorders: pilot study on early effects on patients' quality of life. Padua L; Aprile I; Caliandro P; Padua R; Mazza S; Tonali P J Peripher Nerv Syst; 2004 Mar; 9(1):3-6. PubMed ID: 14871448 [TBL] [Abstract][Full Text] [Related]
36. Intravenous immunoglobulin: striving for appropriate use. Kumar A; Teuber SS; Gershwin ME Int Arch Allergy Immunol; 2006; 140(3):185-98. PubMed ID: 16682800 [TBL] [Abstract][Full Text] [Related]
37. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders. Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589 [TBL] [Abstract][Full Text] [Related]
38. The use of intravenous immunoglobulin in autoimmune bullous diseases. Chee SN; Murrell DF Immunol Allergy Clin North Am; 2012 May; 32(2):323-30, viii. PubMed ID: 22560145 [TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Rütter A; Luger TA Curr Opin Investig Drugs; 2002 May; 3(5):713-9. PubMed ID: 12090544 [TBL] [Abstract][Full Text] [Related]
40. Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues. Gold R; Stangel M; Dalakas MC Nat Clin Pract Neurol; 2007 Jan; 3(1):36-44. PubMed ID: 17205073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]